Confo Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 77
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.19M
Latest Deal Amount
  • Investors
  • 15

Confo Therapeutics General Information

Description

Developer of a drug discovery technology designed to address unmet medical needs. The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies which stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry to be provided with novel pathway-selective agonists for improved therapeutic intervention.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Therapeutic Devices
Primary Office
  • Technologiepark 94
  • Zwijnaarde
  • 9052 Ghent
  • Belgium

Confo Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Confo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 30-Mar-2021 $1.19M 000.00 Completed Generating Revenue
5. Grant 20-Jun-2019 00.000 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 01-May-2019 000.00 000.00 0000 Completed Generating Revenue
3. Grant 20-Feb-2018 00.000 00.000 Completed Generating Revenue
2. Grant 01-Feb-2017 $2.74M $7.28M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Feb-2016 $7.28M $7.28M Completed Generating Revenue
To view Confo Therapeutics’s complete valuation and funding history, request access »

Confo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B2 0,000,000 00.00 00.00 00 00.00 00.000
Class B 000,000 00.00 00.00 00 00.00 00.000
To view Confo Therapeutics’s complete cap table history, request access »

Confo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery technology designed to address unmet medical needs. The company is building a portfolio of
Drug Discovery
Ghent, Belgium
77 As of 2021
000.00
0000000000 000.00

0000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ex
0000 000000000
La Jolla, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Boston, MA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confo Therapeutics Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed Menlo Park, CA 0 00.00 000000&0 00.00
000000 00000000000 Formerly VC-backed Columbia, MD 000 000.00 000000&0 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 25 competitors. Get the full list »

Confo Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Cedric Ververken Ph.D Chief Executive Officer & Board Member
Paolo Vicini Chief Development Officer
Christel Menet Ph.D Chief Scientific Officer
Frank Landolt Chief Counsel, Intellectual Property and Legal
Toon Laeremans Ph.D Co-Founder & Head of Technology
You’re viewing 5 of 7 executive team members. Get the full list »

Confo Therapeutics Board Members (15)

Name Representing Role Since
Alexandra Tolia Ph.D Fund+ Board Member 000 0000
Andrew Rice MD Self Chairman of Medical Advisory Board 000 0000
Cedric Ververken Ph.D Confo Therapeutics Chief Executive Officer & Board Member 000 0000
Christina Takke Ph.D V-Bio Ventures Board Member 000 0000
Edward Van Wezel BioGeneration Ventures Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Confo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confo Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGeneration Ventures Venture Capital Minority 000 0000 000000 0
Fund+ Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Wellington Partners Venture Capital Minority 000 0000 000000 0
Vlaanderen verbeelding werkt Limited Partner 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »